Speaker illustration

Doctor Mark Nidorf

GenesisCare Western Australia, Perth (Australia)

Dr Stefan Mark Nidorf trained in Medicine in Perth Western Australia. He did advanced training in echocardiography at the Massachusetts General Hospital, Boston, Harvard Medical School. He is currently working as a Clinical Cardiologist at GenesisCare in Perth and is affiliated with the Heart and Vascular Research Institute at the Perkins Research Institute. His clinical research interest in atherosclerosis led him to initiate the LoDoCo trials of low dose colchicine for the secondary prevention of coronary disease, the rationale of which has been strengthened by an improved understanding of how cholesterol transitions from an essential molecule into a crystalline form that can act to initiate and perpetuate the chronic and acute manifestations of atherosclerosis

12-month post-trial follow-up of participants in the Australian arm of the second low-dose colchicine trial

Event: ESC Congress 2021 - The Digital Experience

Topic: Prevention

Session: Chronic coronary syndromes: pathophysiology, treatment, and prognosis

Thumbnail

Targeting inflammation with colchicine in patients with acute coronary syndromes.

Event: ACVC 2021

Topic: Acute Cardiac Care

Session: Inflammation and hypoxia as therapeutic targets in acute cardiovascular care

Thumbnail

LoDoCo2 - Colchicine in Patients With Chronic Coronary Disease

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Chronic Ischaemia

Session: Hot Line LoDoCo2

Thumbnail

Hot Line LoDoCo2.

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Chronic Ischaemia

Session: Hot Line LoDoCo2

Thumbnail

This platform is supported by

logo Novo Nordisk